Andrew N Billin1. 1. GlaxoSmithKline, Inc., 5 Moore Drive, Research Triangle Park, NC 27709, USA. andrew.n.billin@gsk.com
Abstract
BACKGROUND: The identification of small molecule agonists for the nuclear receptor peroxisome proliferator-activated receptor beta/delta (PPAR-beta/delta, NR1C2) has enabled the characterization of this receptor's functions in preclinical models. Subsequently, a number of small molecule agonists of PPAR-beta/delta have been progressed into clinical trials. OBJECTIVE: This review will examine the major preclinical findings that underpin the hypothesis that PPAR-beta/delta agonists may be beneficial in treating dyslipidemia and Type 2 diabetes, as well as emerging clinical data with a variety of PPAR-beta/delta agonists. METHODS: The literature concerning preclinical experiments that combine in vivo and in vitro mechanistic studies are reviewed and compared with the results of the early clinical trials. CONCLUSIONS: Thus far, the activities of the agonists seen in the clinic are broadly similar to those seen in preclinical models. However, it is still not known if PPAR-beta/delta agonists will truly be differentiated enough from current treatments to justify their use in treating dyslipidemia or Type 2 diabetes. Major challenges for the development of PPAR-beta/delta agonists exist and the path forward is as yet undefined.
BACKGROUND: The identification of small molecule agonists for the nuclear receptor peroxisome proliferator-activated receptor beta/delta (PPAR-beta/delta, NR1C2) has enabled the characterization of this receptor's functions in preclinical models. Subsequently, a number of small molecule agonists of PPAR-beta/delta have been progressed into clinical trials. OBJECTIVE: This review will examine the major preclinical findings that underpin the hypothesis that PPAR-beta/delta agonists may be beneficial in treating dyslipidemia and Type 2 diabetes, as well as emerging clinical data with a variety of PPAR-beta/delta agonists. METHODS: The literature concerning preclinical experiments that combine in vivo and in vitro mechanistic studies are reviewed and compared with the results of the early clinical trials. CONCLUSIONS: Thus far, the activities of the agonists seen in the clinic are broadly similar to those seen in preclinical models. However, it is still not known if PPAR-beta/delta agonists will truly be differentiated enough from current treatments to justify their use in treating dyslipidemia or Type 2 diabetes. Major challenges for the development of PPAR-beta/delta agonists exist and the path forward is as yet undefined.
Authors: Muralimohan Yepuru; Jeetendra Eswaraka; Jeffrey D Kearbey; Christina M Barrett; Sharan Raghow; Karen A Veverka; Duane D Miller; James T Dalton; Ramesh Narayanan Journal: J Biol Chem Date: 2010-07-23 Impact factor: 5.157
Authors: Anna Leonardini; Luigi Laviola; Sebastio Perrini; Annalisa Natalicchio; Francesco Giorgino Journal: PPAR Res Date: 2010-02-23 Impact factor: 4.964
Authors: Liraz Levi; Glenn Lobo; Mary Kathryn Doud; Johannes von Lintig; Darcie Seachrist; Gregory P Tochtrop; Noa Noy Journal: Cancer Res Date: 2013-05-30 Impact factor: 12.701
Authors: Prajakta S Palkar; Michael G Borland; Simone Naruhn; Christina H Ferry; Christina Lee; Ugir H Sk; Arun K Sharma; Shantu Amin; Iain A Murray; Cherie R Anderson; Gary H Perdew; Frank J Gonzalez; Rolf Müller; Jeffrey M Peters Journal: Mol Pharmacol Date: 2010-06-01 Impact factor: 4.054
Authors: Combiz Khozoie; Michael G Borland; Bokai Zhu; Songjoon Baek; Sam John; Gordon L Hager; Yatrik M Shah; Frank J Gonzalez; Jeffrey M Peters Journal: BMC Genomics Date: 2012-11-24 Impact factor: 3.969